Study Flaws, Data Integrity Issues Clog China Review System As Applications Soar

Total Filings Processed Up 33%

Facing a 40% increase in investigational new drug applications, regulatory reviewers in China are scrambling to turn down hundreds of filings plagued by major study design flaws, inconsistent samples and quality control failures.

China growth
CHINA NEW DRUG FILINGS SOAR BUT DATA AND STUDY ISSUES REMAIN • Source: Alamy

To find how prevalent problems are in regulatory filings to start clinical trials and for product approvals in China, one doesn’t have to read far within China’s annual report on new drug reviews, released on 21 June by the National Medical Products Administration (NMPA), to find out.

In 2020, the regulatory agency approved 20 innovative new products, including 14 drugs, four traditional Chinese medicines and two biologics....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Approval Standards

More from Pathways & Standards

US FDA’s Second Half 2025 User Fee Goals Swing Toward Respiratory Disease

 

The 43 novel agents with user fee goal dates in the remainder of 2025 have fewer oncologics and infectious disease drugs than the first half of the year.

Consumer Groups Have A ‘Radical Transparency’ List For US FDA’s PDUFA VIII

 

Development of the user fee commitment letter largely takes place behind closed doors between industry and FDA. Outside groups see the upcoming negotiation cycle as a chance to change this and other agency information blocks by reminding Commissioner Makary of his commitment to transparency.

Senate Bill Would Boost Oversight Of US FDA User Fee Program Following Trump Reorganization

 

Senate appropriators also put FDA on notice regarding recent meetings and compliance with the Federal Advisory Committees Act, signal positive news on rare pediatric diseases, and offer hints of other agency areas they have close eyes on.